Avella Selected by Takeda Pharmaceuticals to Distribute Ninlaro

PRESS RELEASE

Avella Specialty Pharmacy announced today that it has been selected by Takeda Pharmaceutical Company Limited to distribute NINLARO® (ixazomib), a medication for individuals diagnosed with multiple myeloma. NINLARO is the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

“NINLARO offers patients a new approach—an all-oral triplet regimen—to treating multiple myeloma with a proteasome inhibitor. Avella’s pharmacists will be working closely with patients to ensure that medication adherence and patient safety are maintained throughout the entire treatment,” saidLeslie Yendro, RN, Vice President of Business Development for Avella Specialty Pharmacy. “Our commitment to providing expert guidance and ongoing support to patients is one of the reasons why manufacturers continue to turn to Avella in order to distribute breakthrough specialty drugs.”

Multiple myeloma is a blood cancer that forms in plasma cells. Plasma cells are found in bone marrow and play a critical role in helping the immune system fight infections. When these cells become cancerous, they can produce tumors called plasmacytomas. Patients with multiple myeloma have more than one of these tumors. NINLARO is a proteasome inhibitor that works by blocking certain enzymes produced by cancerous cells, which in turn prevents these cells from surviving and growing.